

SUN - 2nd Mar 2025		PRE-LUNCH SESSION	MON - 3rd Mar 2025		TUE - 4th Mar 2025		WED - 5th Mar 2025		THUR - 6th Mar 2025		FRI - 7th Mar 2025		SAT - 8th Mar 2025	
			0830-0930	Overview and doubts - PRIYA, PRAMESH, MANJU, GIRISH	0830-0900	Phases of trials and Phase I trials: LIZ GARETH MAYER	0830-0915	Association and regression: ALLAN HACKSHAW	0830-0900	Biomarkers in research: HARISANKARAN (virtual)	0830-0900	Handling missing data: SALLY HUNSBERGER (virtual)	0830-0900	Writing a research paper - BALU KRISHNA SASIDHARAN
					0900-0930	Phase II trials: MARK KRAILO	0915-0945	Implementation research - CAITLYN DUFFY	0900-0930	Non-inferiority studies - MAX PARMAR	0900-0930	Systematic reviews: CHRIS FRAMPTON	0900-0930	Quality improvement - PAOLA FRIEDRICH
			0930-1015	Patient and public participation in research - RICHARD STEPHENS	0930-1010	Methodological aspects of phase III trials: PRAMESH	0945-1015	Sample size for observational studies:	0930-1000	Screening Trials - ISABELLE	0930-1000	Multiple testing: MARC BUYSE	0930-1000	Critical appraisal of published papers: IAN
			1015-1045	Tea break	1010-1040	Tea break	1045-1115	Tea break	1000-1030	Designing trials in smaller populations: MATT SYDES	1000-1030	Question time: Open forum	1000-1030	NCG and research collaboration - PRAMESH
			1045-1130	Pretest (participants) Briefing (faculty)	1040-1120	Statistics for phase III trials: MARC BUYSE	1115-1145	Qualitative research methods: DYLAN GRAETZ	1100-1130	Question time: Open forum	1100-1130	Predictive and prognostic factors: MARC BUYSE	1100-1145	Feedback session
			1130-1215	Overview of workshop: PRIYA RANGANATHAN	1120-1200	Observational study designs: CHRIS FRAMPTON	1145-1225	Protocol writing: Outcomes and outcome measures: MARC BUYSE	1130-1215	Survival Analysis: ALLAN HACKSHAW	1130-1210	Novel study designs: MAHESH PARMAR		
			1215-1300	Protocol writing: Introduction/Hypothesis/Aims/Objectives: MICHAEL BRADA	1200-1300	Protocol writing: Methods: MARTIN STOCKLER	1225-1300	Composite and surrogate endpoints: ALLAN HACKSHAW	1215-1300	Patient-reported outcomes & Quality of Life measures: JAMMBE MUSORO	1235-1300	Grant writing: DUNCAN GILBERT	1210-1235	Practical aspects of running a trial - RUTH LANGLEY
			1300-1400	Lunch	1300-1400	Lunch	1300-1400	Lunch	1300-1400	Lunch	1300-1400	Lunch	1230-1330	Lunch
			1400-1630 (tea break in between)	Protocol development session: concept sheets -	1400-1700 (tea break in between)	Protocol development session: Study design, Setting, Population, Intervention	1400-1700: (tea break in between)	Protocol development session: Outcomes & measures, Statistical considerations	1400-1630 (tea break in between)	Protocol development session: Overall discussions	1400-1600 (tea break in between)	Protocol development session: Final discussions		
			1700-1745	Focus small group sessions	1700-1830	Team-building activity	1715-1800	Focus small group sessions	1645-1730	Focus small group sessions	1600-1700	Meet-the-expert sessions	1800-2100	ASCO joint session
1700-1830	Arrival and settling down		1900 onwards	Keynote address and Welcome dinner (national costumes)					1730-1830	Meet-the-expert sessions				
1830-1930	Registration and pre-workshop session													
			Homework (due by 2100) - update concept sheet and protocol each day	Background/rationale, Aim, objectives & hypothesis	Homework (due by 2100) - update concept sheet and protocol each day	Study design, Setting, Population, Intervention, Study procedures	Homework (due by 2100) - update concept sheet and protocol each day	Outcomes & measures, Statistical considerations	Homework (due by 2100) - update concept sheet and protocol each day	Finalising the concept sheet and protocol	Homework	Final concept sheet and protocol to be submitted		